Cargando…
Correction to: Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
Autores principales: | Leung, Christopher Kai Shun, Ren, Seraph Tianmin, Chan, Poemen Pui Man, Wan, Kelvin Ho Nam, Kam, Aziz Ka Wai, Lai, Gilda Wing Ki, Chiu, Vivian Sheung Man, Ko, Match Wai Lun, Yiu, Cedric Ka Fai, Yu, Marco Chak Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832638/ https://www.ncbi.nlm.nih.gov/pubmed/35144657 http://dx.doi.org/10.1186/s13063-022-06079-1 |
Ejemplares similares
-
Nicotinamide riboside as a neuroprotective therapy for glaucoma: study protocol for a randomized, double-blind, placebo-control trial
por: Leung, Christopher Kai Shun, et al.
Publicado: (2022) -
Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells
por: Fletcher, Rachel S., et al.
Publicado: (2017) -
Nicotinamide Riboside and Dihydronicotinic Acid Riboside Synergistically Increase Intracellular NAD(+) by Generating Dihydronicotinamide Riboside
por: Ciarlo, Eleonora, et al.
Publicado: (2022) -
Dihydronicotinamide riboside: synthesis from nicotinamide riboside chloride, purification and stability studies
por: Zarei, Amin, et al.
Publicado: (2021) -
The Clinical Effects of Nicotinamide Riboside on Inflammatory Parameters
por: Kwon, Jun, et al.
Publicado: (2022)